The CAR T-cell race: The rules of the game.
Adriana Cristina BalduzziPublished in: British journal of haematology (2024)
The management of paediatric patients with refractory acute lymphoblastic leukaemia eligible for the CAR T cell product tisagenlecleucel involves multiple decision points between the process of patient referral to product infusion. How to address the individual patient's circumstances, optimize apheresis yields and, above all, plan the best bridging chemotherapy is clearly detailed in these comprehensive and practical recommendations by Kumar Mishra and colleagues. Commentary on: Mishra et al. Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19381.
Keyphrases
- cell therapy
- liver failure
- respiratory failure
- case report
- stem cells
- primary care
- mesenchymal stem cells
- drug induced
- emergency department
- healthcare
- low dose
- intensive care unit
- social media
- clinical practice
- single cell
- health information
- locally advanced
- decision making
- radiation therapy
- extracorporeal membrane oxygenation
- bone marrow
- chemotherapy induced
- liquid chromatography